- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00126490
Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
Phase 2 Trial of Sequential Bevacizumab Then Subcutaneous Interleukin-2 in Metastatic Renal Cancer
Study Overview
Status
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. Determine the frequency of major response in patients with metastatic renal cell cancer treated with bevacizumab and interleukin-2.
SECONDARY OBJECTIVES I. Compare the median progression-free survival and median overall survival of patients treated with this regimen with risk-stratified historical controls from published risk models.
OUTLINE:
Patients receive bevacizumab IV over 30-90 minutes on day 1 in weeks 1, 3, 5, 7, 9, and 11. Patients also receive interleukin-2 subcutaneously on days 1-5 in weeks 5-10. Treatment repeats every 12 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease then receive bevacizumab alone in weeks 1, 3, 5, 7, 9, and 11. Courses with bevacizumab alone repeat every 12 weeks in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed at 30 days and then every 3 months for at least 2 years.
PROJECTED ACCRUAL: Approximately 10-38 patients will be accrued for this study within 21 months.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Florida
-
Tampa, Florida, United States, 33612
- Moffitt Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Histologically or cytologically confirmed renal cell cancer
- Metastatic disease
- More than 75% clear cell histology
- Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral CT scan
- No prior refractory disease, defined as clinical or radiologic progression, during or within 3 months after completion of prior interleukin-2 (IL-2)
Nominally "good" or "intermediate" risk disease, meeting ≥ 4 out of 5 of the following criteria:
- Hemoglobin > 10 g/dL (except for patients with hereditary hemoglobinopathy)
- ECOG performance status 0-1 (required)
Calcium normal (corrected)
- Patients with hypercalcemia due to malignancy allowed provided it has been controlled for > 1 month
- Primary tumor treated or resected by complete nephrectomy, partial nephrectomy, radiofrequency ablation, or other local ablation
- Lactic dehydrogenase < 1.5 times upper limit of normal (ULN)
- No history of or current brain or CNS metastasis by CT scan or MRI within the past 30 days
- Performance status - ECOG 0-1
- More than 4 months
- Absolute neutrophil count ≥ 1,500/mm^3
- Platelet count ≥ 75,000/mm^3
- No history of bleeding diathesis
- PTT < 1.5 times ULN
- INR < 1.5
- Bilirubin ≤ 1.5 times ULN
- AST and ALT ≤ 2.5 times ULN
- No chronic hepatitis B or C
- Creatinine ≤ 2.0 mg/dL
- No proteinuria* by dipstick urinalysis
- Urine protein ≤ 1,000 mg by 24-hour urine collection
- No symptomatic congestive heart failure
- No uncontrolled hypertension, defined as systolic blood pressure (BP) > 160 mm Hg and diastolic BP > 90 mm Hg
- No cardiac arrhythmia
- No peripheral vascular disease ≥ grade 2
- No clinically significant peripheral artery disease
None of the following arterial thromboembolic events within the past 6 months:
- Transient ischemic attack
- Cerebrovascular accident
- Unstable angina pectoris
- Myocardial infarction
- Not pregnant
- No nursing during and for 3 months after completion of study treatment
- Negative pregnancy test
- Fertile patients must use effective contraception before, during, and for 3 months after completion of study treatment
- No active infection requiring parenteral antibiotics
- No known HIV positivity
- No history of allergic reaction to antibody drugs or IL-2
- No psychiatric illness or social situation that would preclude study compliance
- No non-healing wound or fracture
- No insulin-dependent diabetes
- No other uncontrolled illness
- No other malignancy requiring active treatment within the past 2 years except nonmelanoma skin cancer
- No prior bevacizumab
- At least 6 months since prior immunotherapy containing IL-2
- At least 2 months since prior investigational antibodies
- More than 4 weeks since prior conventional cytotoxic chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered
- No concurrent corticosteroids except replacement corticosteroids for adrenal insufficiency OR inhaled steroids for chronic obstructive pulmonary disease, asthma, or allergic rhinitis
- More than 3 weeks since prior radiotherapy and recovered
- No prior radiotherapy to the only site of measurable disease unless there has been subsequent disease progression
- More than 4 weeks since prior major surgery
- At least 24 hours since prior minor surgical procedure, placement of vascular access device, or fine needle aspiration
- At least 30 days since prior and no other concurrent investigational agents
More than 10 days since prior anticoagulants
- Low-dose anticoagulants for maintenance of vascular access device patency allowed
- No concurrent therapeutic warfarin, including warfarin for treatment of deep vein thrombosis or pulmonary embolism
- No other concurrent anticancer therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (bevacizumab, aldesleukin)
Patients receive bevacizumab IV over 30-90 minutes on day 1 in weeks 1, 3, 5, 7, 9, and 11.
Patients also receive interleukin-2 subcutaneously on days 1-5 in weeks 5-10.
Treatment repeats every 12 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.
Patients with stable or responding disease then receive bevacizumab alone in weeks 1, 3, 5, 7, 9, and 11.
Courses with bevacizumab alone repeat every 12 weeks in the absence of disease progression or unacceptable toxicity.
|
Correlative studies
Given IV
Other Names:
Given subcutaneously
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Evaluable Participants With Complete Response (CR) and Partial Response (PR) at One Year
Time Frame: 1 year
|
Major response according to Response Evaluation Criteria In Solid Tumors (RECIST).
CR: Disappearance of all target lesions; Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm.
PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Evaluable Participants With Overall Survival (OS) at 2 Years
Time Frame: 2 years from start of treatment
|
Overall Survival tabulation at 2 years from start of treatment.
|
2 years from start of treatment
|
Number of Evaluable Participants With Progression Free Survival (PFS)
Time Frame: Up to 2 years
|
Progression Free Survival tabulation at 1 year and at 2 years.
Progressive Disease (PD): Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.
|
Up to 2 years
|
Pearson Correlation Coefficients of Dendritic Cell (DC):Immature Cell (ImC) Ratio With DC Function
Time Frame: At baseline, at days 4-5, 9-10 (of course 1), and at the end of treatment
|
Dendritic cell (DC) phenotype or functionality.
Pearson correlation coefficients of DC:ImC ratio with DC function were to be computed and tested for departure from zero.
Those with major responses were to be compared to those without major responses with respect to baseline DC:ImC ratio, baseline DC functional assay, post-treatment DC:ImC ratio and post-treatment DC functional assay using pooled t tests.
|
At baseline, at days 4-5, 9-10 (of course 1), and at the end of treatment
|
Number of Participants With Possibly Related Serious Adverse Events (SAEs)
Time Frame: Up to 30 days after completion of treatment
|
Number of Participants with Serious Adverse Events (SAEs) Possibly Related to Study Treatment.
Toxicity as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 3.0
|
Up to 30 days after completion of treatment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mayer Fishman, Moffitt Cancer Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Kidney Diseases
- Urologic Diseases
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Kidney Neoplasms
- Carcinoma, Renal Cell
- Physiological Effects of Drugs
- Anti-Infective Agents
- Peripheral Nervous System Agents
- Antiviral Agents
- Anti-HIV Agents
- Anti-Retroviral Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Antineoplastic Agents
- Immunologic Factors
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Aldesleukin
- Antibodies
- Immunoglobulins
- Bevacizumab
- Antibodies, Monoclonal
- Antineoplastic Agents, Immunological
- Immunoglobulin G
- Interleukin-2
- Endothelial Growth Factors
Other Study ID Numbers
- NCI-2012-02663 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- P30CA076292 (U.S. NIH Grant/Contract)
- CDR0000434852
- NCI-6438
- MCC-IRB-102782
- MCC 13921 (Other Identifier: Moffitt Cancer Center)
- 6438 (Other Identifier: CTEP)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Renal Cell Carcinoma
-
Peloton Therapeutics, Inc.Active, not recruitingKidney Cancer | Renal Cell Carcinoma | Renal Cancer | Renal Cell Carcinoma (RCC) | Renal Cell Cancer Metastatic | Kidney | Clear Cell Renal Cell Carcinoma (ccRCC) | Renal Cell Carcinoma Recurrent | Renal Cell Cancer, RecurrentUnited States
-
National Cancer Institute (NCI)CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell CarcinomaUnited States
-
Telix International Pty LtdGrand Pharmaceutical (China) Co., Ltd.CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Cancer | Suspected Recurrent Renal Clear Cell CarcinomaChina
-
National Cancer Institute (NCI)CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell CarcinomaUnited States, Taiwan, Australia
-
National Cancer Institute (NCI)TerminatedSorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney CancerClear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer | Papillary Renal Cell CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Stage IV Renal Cell CancerCanada
-
National Cancer Institute (NCI)CompletedRecurrent Renal Cell Carcinoma | Stage IV Renal Cell CancerCanada
-
National Cancer Institute (NCI)M.D. Anderson Cancer CenterCompletedClear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Stage IV Renal Cell CancerUnited States
-
NewLink Genetics CorporationCompletedMetastatic Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Metastatic Kidney Cancer | Refractory Renal Cell Carcinoma | Metastatic Clear-cell Renal CancerUnited States
Clinical Trials on Laboratory Biomarker Analysis
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedProstate Cancer
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingLeukemia | Acute Lymphoblastic Leukemia | Acute Promyelocytic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUntreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnClear Cell Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Childhood Kidney NeoplasmUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)WithdrawnBreast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedWilms Tumor and Other Childhood Kidney TumorsUnited States